Which medications increase norepinephrine levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Medications That Elevate Norepinephrine Levels

Multiple drug classes increase norepinephrine levels through different mechanisms, with the most clinically relevant being norepinephrine reuptake inhibitors (atomoxetine, viloxazine), serotonin-norepinephrine reuptake inhibitors (venlafaxine, duloxetine), tricyclic antidepressants (nortriptyline, desipramine), bupropion, stimulants (methylphenidate, amphetamines), and direct norepinephrine administration.

Primary Norepinephrine-Elevating Medications

Selective Norepinephrine Reuptake Inhibitors (NRIs)

  • Atomoxetine is the prototypical selective NRI that increases synaptic noradrenaline by binding to the norepinephrine transporter, and also increases dopamine in the prefrontal cortex where dopamine transporters are scarce 1, 2.

  • Viloxazine exhibits moderate inhibitory effects on the norepinephrine transporter and increases serotonin levels in the prefrontal cortex, with moderate activity at noradrenergic and dopaminergic systems 1.

  • These agents are particularly effective in patients with normal or high baseline norepinephrine levels, especially those with impaired central autonomic pathways 2.

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

  • Venlafaxine and duloxetine increase both serotonin and norepinephrine levels, though they have been reported to cause slight weight increases over long-term treatment 3.

  • The noradrenergic action of these dual-mechanism drugs is related to improvements in motor activity, attention, and arousal 4.

Tricyclic Antidepressants with Noradrenergic Action

  • Nortriptyline and desipramine have prevalent noradrenergic effects among the tricyclic class 3, 4.

  • Amitriptyline is the most potent inducer of weight gain among tricyclics but also has significant noradrenergic activity 3.

  • Imipramine appears to have a neutral effect on weight, suggesting balanced neurotransmitter effects 3.

Atypical Antidepressants

  • Bupropion selectively inhibits reuptake of dopamine and, to a lesser extent, norepinephrine, and is the only antidepressant that consistently causes weight loss 3, 4.

  • Mirtazapine enhances noradrenergic transmission through its noradrenergic and specific serotoninergic mechanism, though it is associated with weight gain 3, 4.

  • Mianserin also enhances noradrenergic transmission 4.

Stimulant Medications

  • Methylphenidate increases synaptic levels of both dopamine and norepinephrine through reuptake inhibition 5.

  • Amphetamines similarly elevate norepinephrine and dopamine levels 1.

  • Mazindol is classified as a central nervous stimulant that inhibits reuptake of norepinephrine, dopamine, and serotonin, and acts as a weak dopamine releasing agent 1.

Atypical SSRI

  • Fluoxetine is unique among SSRIs in that it robustly increases extracellular concentrations of norepinephrine and dopamine in addition to serotonin in the prefrontal cortex, unlike other SSRIs (citalopram, fluvoxamine, paroxetine, sertraline) 6.

  • This effect may be due to fluoxetine's ability to block 5-HT2C receptors at therapeutic concentrations (242 nM), making it an atypical SSRI 6.

Monoamine Oxidase Inhibitors (MAOIs)

  • MAOIs block the breakdown of serotonin, noradrenaline, and dopamine, thereby increasing the availability of all three monoamines 4.

Atypical Antipsychotic

  • Quetiapine's antidepressant effect is likely related to the noradrenergic action of its metabolite norquetiapine 4.

Direct Vasopressor Administration

Injectable Norepinephrine

  • Norepinephrine administered directly increases systemic norepinephrine levels and is commonly used to manage hypotension during anesthesia induction 7.

  • When given as a prophylactic bolus (0.1 mg/kg) during anesthesia induction, norepinephrine causes a 37% relative reduction in heart rate and 30% reduction in systolic arterial pressure from baseline 7.

Other Vasopressors

  • Ephedrine (0.1 mg/kg) is more effective than norepinephrine for prophylactic use during anesthesia, maintaining blood pressure and cardiac output better, with only a 20% reduction in systolic pressure and 17% reduction in heart rate 7.

  • Phenylephrine (1 μg/kg) shows similar hemodynamic patterns to norepinephrine with short duration of action 7.

Important Clinical Considerations

Cardiovascular Effects

  • Calcium channel blockers have variable effects on norepinephrine: nifedipine retard transiently increases norepinephrine levels (2-4 hours), while amlodipine induces sustained rises in basal norepinephrine levels by more than 50% after chronic therapy 8.

  • Methylphenidate's norepinephrine-elevating effects can rarely cause acute cardiomyopathy and pericarditis, particularly after single doses in susceptible individuals 5.

Weight Considerations

  • When selecting antidepressants, the noradrenergic action must be balanced against weight effects: bupropion causes weight loss (-1.3 kg), while mirtazapine causes weight gain (+1.5 kg) despite both having noradrenergic activity 3.

Mechanism-Based Selection

  • Pure noradrenergic action may not be sufficient for full antidepressant effect, but pronoradrenergic action represents an important element for increasing efficacy of mixed-action antidepressants 4.

  • The norepinephrine transporter is responsible for >90% of norepinephrine uptake in the autonomic neuroeffector junction, making NET inhibitors particularly potent 2.

References

3
Guideline

pharmacological management of obesity: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

How should norepinephrine be tapered in an ICU patient, and what clinical parameters should be monitored during the taper?
For a 21‑year‑old male with mild hypertension (office BP 153/82 mmHg, home average 122/65 mmHg), a small atrial septal defect, allergic rhinitis, mild hyperlipidaemia, and a BMI of 23, what ASA (American Society of Anesthesiologists) physical status classification is appropriate?
In a 25-year-old patient with a total cholesterol of 291 mg/dL and triglycerides of 412 mg/dL, what treatment should be initiated?
What is the appropriate management for a 27-year-old female with total cholesterol of 219 mg/dL, LDL cholesterol of 139 mg/dL, and apolipoprotein B of 104 mg/dL?
Is a 20‑lb weight gain by 26 weeks gestation appropriate for a woman with a normal pre‑pregnancy BMI, and what dietary and activity recommendations should I follow?
Is Augmentin (amoxicillin‑clavulanate) appropriate for empiric treatment of bacterial meningitis in an adult with an 8‑day migraine‑type headache, recent flu‑like illness, new neck stiffness, and a normal brain MRI?
How should mild nausea after gadolinium-based contrast MRI be managed?
What should be done for a patient who develops palpitations after increasing Vyvanse (lisdexamfetamine) to 30 mg?
What is the best peripheral nerve block for intramedullary tibial nailing?
Can I prescribe hydrocortisone for itching due to hand‑foot‑and‑mouth disease in a child?
Is calamine lotion appropriate for relieving itching in a child with hand‑foot‑and‑mouth disease, and what is the proper application regimen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.